A TMC-based organization supporting innovation pediatric medical devices has secured a $7.4 million grant. Photo via tmc.edu

The Southwest National Pediatric Device Innovation Consortium announced this month that it has received a $7.4 million grant from the Food and Drug Administration to continue developing innovative pediatric medical devices.

Led by Baylor College of Medicine and Texas Children’s Hospital, SWPDC supports the development and commercialization of devices relating to children's health, including synthetic pediatric heart valves, miniature injection devices and neonatal intensive care unit monitoring devices, according to a statement from Baylor.

According to Dr. Chester Koh, SWPDC executive director and principal investigator, who is also a professor of urology at Baylor and a pediatric urologist at Texas Children’s, physicians today often have to treat pediatric patients with devices that are designed for larger adult bodies.

"This grant allows us to continue to spur development of devices specifically designed for kids by providing funding, consulting, clinical expertise and other assistance, all of which is made possible by our co-existence in the healthcare innovation ecosystem of the Texas Medical Center,” he said in the statement.

The SWPDC received a similar five-year grant in 2018 from the FDA, and has since added 200 pediatric device projects in all stages of development to its portfolio, raising in total more than $200 million in follow-on funding for the technology. It's one of five consortia in the FDA’s Pediatric Device Consortia (PDC), with others in Pennsylvania, Washington D.C., the San Francisco Bay Area, and Los Angeles.

Regionally, the consortium members include engineers from Texas A&M University, Rice University, University of Houston and the University of Minnesota, as it looks to expand into the midwest. It also partners with Texas Medical Center Innovation, JLABS@TMC and Proxima CRO.

In addition to the $7.4 million grant, SWPDC also received funding for its real-world data/real-world evidence (RWD/RWE) demonstration projects that focus on postoperative cardiac care, according to BCM.

Earlier this summer, Houston-based medtech company CorInnova was one of five companies invited to invited to present pitches at the National Capital Consortium for Pediatric Device Innovation’s “Make Your Medical Device Pitch for Kids!” competition. The event takes place this month and the companies are competing for a share of $150,000 in grant funding from the FDA. CorInnova has developed a minimally invasive device for the treatment of congestive heart failure.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston healthtech startup raises $30M to scale surgical healing gel

fresh funding

Houston-based healthtech startup TYBR Health has raised a $30 million Series A round to scale its B3 GEL System, which helps protect tendons from scarring after surgery.

The round was led by Minneapolis-based Vensana Capital and Cleveland-based Mutual Capital Partners, with participation from Denver-based Neovate Capital Partners and existing investors, according to a news release from the company.

TYBR Health said it plans to use the funding to broaden the B3 GEL System's clinical applications, expand commercialization and conduct studies to evaluate its ability to protect tissue and improve healing outcomes.

"Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals. That part of the equation has gone largely unaddressed ... There's a shift underway across surgical specialties, from focusing almost entirely on the mechanical repair to also weighing the biological conditions that repair needs to succeed," Tim Keane, co-founder and CEO of TYBR Health, said in the news release. "This financing lets us reach more surgeons and generate the clinical evidence to move that shift forward."

As part of the financing round, Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will join the TYBR board, alongside independent director Aaron Smith.

"TYBR Health is addressing a gap surgeons have lived with for a long time, with a product that fits the way they already work," Zambory, principal at Mutual Capital Partners, added in the release. "We're excited to co-lead this round and support the company's growth."

TYBR was founded in 2020 and originated from the TMCi’s Biodesign fellowship and participated in the TMC's Accelerator for HealthTech. Its B3 GEL System is a flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles, and the surrounding soft tissue while they heal from orthopedic surgery. It received FDA 510(k) clearance last June and launched an Australian clinical trial in the fall.

The B3 GEL System has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures since it launched, according to the company, and was first used in the clinical setting earlier this year by Dr. Tammam Hanna with Texas Tech University Health Sciences Center.

Houston space companies win NASA funding to build Mars exploration robots

mission to mars

Two Houston-area spacetech companies have landed a portion of a $17 million award from NASA to develop robots for exploring the surface of Mars, the agency announced this month.

Houston-based Inuitive Machines and Webster, Texas-based MEI Technologies, which does business as Aegis Aerospace, were among the seven companies selected to receive the funding from NASA's Science Transport and Robotic Innovation for Deployment and Exploration (STRIDE) initiative.

According to the release from NASA, the companies are tasked with creating "innovative mobility systems" that would allow future Mars missions to access more challenging terrain and difficult-to-reach regions of the planet, and to travel farther distances. NASA estimated that the work will begin this fall.

NASA solicited proposals for participants in the STRIDE initiative in January. The seven named companies are the first selected to participate in the program.

The additional five companies to receive STRIDE funding include:

"STRIDE demonstrates NASA’s commitment to strong public-private partnerships, allowing the agency to explore new approaches for Mars surface exploration while identifying key capability gaps and development needs for commercial systems that could operate and traverse realistic Martian environments," NASA shared in the announcement.

Last month, Intuitive Machines was awarded $148.3 million to deliver its Nova-C lander to the moon. The funding was part of $600 million the space agency awarded to three companies as part of its Moon Base Program and was Intuitive Machines' sixth task order under NASA's Commercial Lunar Payload Services (CLPS) program. Astrobotic was also one of the companies to land funding for the Moon Base program, as well as Austin-based Firefly Aerospace.

Around the same time, Firefly Aerospace was awarded a $13 million subcontract from NASA’s Jet Propulsion Laboratory to develop technology for NASA’s SkyFall mission to Mars. The mission aims to deploy three Mars helicopters to "perform science and demonstrate airborne subsurface mapping and resource prospecting on the planet." Read more here.